Access cutting-edge autosomal recessive polycystic kidney disease treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Cleveland location
Preparing your pre-screening questions…
Access autosomal recessive polycystic kidney disease specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related autosomal recessive polycystic kidney disease treatment provided free
Check if you qualify for this autosomal recessive polycystic kidney disease clinical trial in Cleveland, OH
No-Cost Study Care
Local to Cleveland
Convenient for OH residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a potentially lethal genetic disorder for which there are currently no disease specific treatments. Clinical trials have been limited by the absence of robust measures of disease progression. The overall goal of this 5 year NIH-funded prospective, observational multicenter study conducted at CC (primary site) and Children's Hospital of Philadelphia (CHOP) (collaborating site) is establish a set of rapid, quantitative, and reproducible novel kidney MRI measures applicable to standard clinical MRI scanners, which could serve as potential biomarkers to measure response to therapy in patients across the disease spectrum and all ages. The investigators will recruit a total of 45 ARPKD patients and 15 healthy controls at the the two sites . All subjects will be \> or = 6yrs old with no contraindications to undergoing MRI (non contrast). ARPKD subjects will be recruited into one of 3 cohorts based on their estimated glomerular filtration rate (eGFR): early CKD (eGFR\> or =90ml/min/1.73m2), mild CKD (60-89ml/min/1.73m2) and moderate CKD (30-59ml/min/1.73m2). For ARPKD subjects, participation will last 3 years and consist of a baseline and 3 subsequent annual visits. Healthy controls will only have 1 study visit. Study visits for all participants will include collection of clinical and demographic data, clinical blood and urine tests (E.g. serum creatinine) and MRI imaging. ARPKD (but not healthy subjects) will also undergo a measured GFR test (iohexol clearance) to accurately assess their kidney function.
Sponsor: The Cleveland Clinic
Yes, this clinical trial (NCT07201025) has an active research site in Cleveland, OH that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for autosomal recessive polycystic kidney disease treatment options in Cleveland, OH, this clinical trial (NCT07201025) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced autosomal recessive polycystic kidney disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all autosomal recessive polycystic kidney disease clinical trials near you to find additional studies recruiting in your area.
See all ankylosing spondylitis clinical trials recruiting in Cleveland — not just this study.
Browse Ankylosing Spondylitis Trials in Cleveland →